Intersect ENT (NASDAQ:XENT) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday.
Several other research firms also recently weighed in on XENT. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Intersect ENT in a research note on Monday, December 11th. JPMorgan Chase & Co. raised Intersect ENT from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Guggenheim reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Intersect ENT in a research note on Friday, December 15th. Zacks Investment Research raised Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Thursday, October 5th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Intersect ENT in a research note on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. Intersect ENT presently has an average rating of “Buy” and a consensus price target of $33.38.
Intersect ENT (NASDAQ XENT) traded up $0.55 during midday trading on Friday, reaching $34.55. The company had a trading volume of 299,179 shares, compared to its average volume of 225,941. Intersect ENT has a 12-month low of $11.75 and a 12-month high of $35.34. The stock has a market cap of $1,017.70, a P/E ratio of -54.84 and a beta of 0.67.
In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $27.78, for a total transaction of $356,500.74. Following the sale, the chief financial officer now owns 27,833 shares in the company, valued at approximately $773,200.74. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gwen R. Carscadden sold 10,000 shares of the stock in a transaction on Friday, January 12th. The shares were sold at an average price of $34.35, for a total value of $343,500.00. Following the sale, the insider now owns 13,856 shares in the company, valued at approximately $475,953.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 178,052 shares of company stock worth $5,703,820. 13.70% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its holdings in shares of Intersect ENT by 39.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 160,883 shares of the medical equipment provider’s stock worth $5,213,000 after purchasing an additional 45,444 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Intersect ENT during the fourth quarter worth $135,000. Simplex Trading LLC acquired a new stake in shares of Intersect ENT during the fourth quarter worth $242,000. GSA Capital Partners LLP acquired a new stake in shares of Intersect ENT during the third quarter worth $926,000. Finally, Iguana Healthcare Management LLC boosted its holdings in shares of Intersect ENT by 28.6% during the third quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the medical equipment provider’s stock worth $2,804,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 86.31% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades Intersect ENT (XENT) to Sell” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/21/bidaskclub-downgrades-intersect-ent-xent-to-sell.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.